Boston, MA, August 2018, Boston Millennia Partners is pleased to announce that the BMP Founders Fund has led a financing for Precision Digital Health (“PDH”). PDH has developed an enterprise software platform, Summa, that enables the integration of disparate clinical data, allowing its customers to run complex queries in real time. Summa is used to integrate information directly from multiple data sources: diagnostic labs, medical devices, clinical trials, wearables, genomic and electronic health records. The company provides efficiency in retrospective data analysis and enables automated repeatable predictive models. A core use case for the system is the construction of synthetic clinical trials. Precision Digital Health’s current customers include pharmaceutical companies, leading clinical research organizations, and life science laboratories.
Ren Roome, Senior Associate at BMP said, “PDH can have a significant impact on the cost and schedule of clinical trials. Thomas Wells, the CEO of PDH, and his team are leaders in the clinical data management space. The company’s technology platform is advanced and offers unique capabilities to the market. As a firm we are committed to building a next generation clinical research platform and PDH can be a foundational part of this solution.”
Thomas Wells said, “As the founding investors in PAREXEL, the BMP team has a unique and successful track record in pharma services businesses. The firm’s expertise and considerable network are valuable additions as we expand our footprint in life sciences.”
PDH was cofounded by Thomas Wells and Michael Bui, CTO. Thomas has over 20 years of experience in life science and healthcare, and specializes in enterprise bioinformatics solutions. Prior to founding Precision Digital Health, Thomas worked at Merck, PAREXEL and Amgen. Michael Bui has over 20 years of experience building enterprise software for life science and healthcare companies. Michael was previously with PAREXEL, OmniComm, and US Labs.
